StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Durable 84-week efficacy improves confidence in Pasatru's clinical value; could drive sentiment and valuation, especially if regulatory and payer pathways remain favorable, though market size is small.
What happened, with direct paths to the underlying reporting
Regeneron announced positive 84-week results from the Phase 3 OPTIMA trial of Pasatru in adults with fibrodysplasia ossificans progressiva (FOP). Data presented at ASBMR show sustained efficacy with reduced HO lesions and flare-ups, plus a consistent safety profile through week 84, supporting long-term disease control and potential for future labeling considerations.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.